Kobayashi Pharmaceutical has patented a method to prevent lidocaine reduction in pharmaceutical compositions. By using linear low-density polyethylene with a side chain carbon number of 4 or lower in the container, the quantity of lidocaine is maintained. GlobalData’s report on Kobayashi Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Kobayashi Pharmaceutical Co Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Kobayashi Pharmaceutical, Nanoemulsion cosmetics was a key innovation area identified from patents. Kobayashi Pharmaceutical's grant share as of January 2024 was 29%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11833123B2) discloses a pharmaceutical composition containing lidocaine and/or its salt, housed in a container with an inner wall made of linear low-density polyethylene. The polyethylene used in the container has a side chain with a carbon number of 4 or less, ensuring the stability of the lidocaine within the composition. Additionally, the density of the linear low-density polyethylene falls within the range of 0.932 to 0.940 g/cm3, further contributing to the efficacy of the pharmaceutical composition.

Furthermore, the patented pharmaceutical composition can exist in the form of a liquid or a gel, providing versatility in its application. The method outlined in the patent aims to prevent the reduction in weight of lidocaine and/or its salt within the composition by utilizing the specific container material and structure. By placing the pharmaceutical composition in a container with the specified linear low-density polyethylene inner wall, which has a side chain with a carbon number of 4 or less, the method ensures the stability and integrity of the lidocaine component. This innovative approach not only safeguards the potency of the pharmaceutical composition but also enhances its shelf-life and effectiveness for medical use.

To know more about GlobalData’s detailed insights on Kobayashi Pharmaceutical, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies